Global Blood Therapeutics

July 11, 2017

Global Blood Expands Sickle Cell Study to Include Kids Ages 6-11

Global Blood Therapeutics has expanded its ongoing HOPE-KIDS 1 trial (NCT02850406), evaluating the investigative GBT440 in pediatric patients with sickle cell disease, to include a new single-dose cohort in younger ... Read more

June 29, 2017

European Agency Grants PRIME Access to GBT440 Therapy for Treatment of SCD

The European Medicines Agency (EMA) has granted GBT440 — Global Blood Therapeutics’ lead drug candidate for sickle cell disease (SCD) — access to its Priority Medicines (PRIME) program. GBT440 is an oral, ... Read more

June 23, 2016

US-based Biopharma Presents Positive Data on Potential Sickle Cell Therapy at European Hematology Congress

Global Blood Therapeutics, a biopharma developing novel therapeutics for the treatment of blood-based disorders, recently announced new results from its ongoing Phase 1/2 study of GBT440-001 in sickle cell disease (SCD). ... Read more

June 6, 2016June 6, 2016

GBT to Review Candidate Data for Sickle Cell on June 10 Webcast

Global Blood Therapeutics, a biopharma focused on the development of innovative therapeutics for the treatment of blood-based disorders such as sickle cell disease (SCD), will host an investor’s webcast at ... Read more